


FilmArray Respiratory Panel

1 Test. 20 Respiratory Pathogens. All in about an hour.




Viruses

- Adenovirus
- Coronavirus HKU1
- Coronavirus NL63
- Coronavirus 229E
- Coronavirus OC43
- Human Metapneumovirus
- Human Rhinovirus/Enterovirus
- Influenza A
- Influenza A/H1
- Influenza A/H1-2009
- Influenza A/H3
- Influenza B
- Parainfluenza 1
- Parainfluenza 2
- Parainfluenza 3
- Parainfluenza 4
- Respiratory Syncytial Virus



Bacteria

- *Bordetella pertussis*
- *Chlamydomphila pneumoniae*
- *Mycoplasma pneumoniae*



**20
Targets**

Simultaneous Detection of 20 Targets

The FilmArray Respiratory Panel tests for a comprehensive panel of 20 respiratory viruses and bacteria. The FilmArray instrument integrates sample preparation, amplification, detection and analysis into one simple system that requires 2 minutes of hands-on time and has a total run time of about 1 hour.

- **Simple:** Two minutes of hands-on time
- **Easy:** No precise measuring or pipetting required
- **Fast:** Turnaround time of about 1 hour
- **Comprehensive:** 20 target respiratory panel

For In-vitro Diagnostic Use
FDA Cleared | CE IVD Marked



If you are interested in a free, no obligation demonstration of the FilmArray in your laboratory visit www.filmarray.com or call 1-800-735-6544.

**FREE
Demo!**

FilmArray®

The fastest way to better results.

Upper Respiratory Tract Infections (URTI)

It is estimated that adults get 2-4 upper respiratory tract infections each year while children average 6-12 upper respiratory tract infections a year. The estimated economic impact of non-influenza related upper respiratory tract infections is \$40 billion annually in the US. ¹


A respiratory tract infection can be the result of one of dozens of viral or bacterial pathogens. The symptoms caused by these different pathogens are nearly indistinguishable, but how a healthcare provider chooses to treat a respiratory infection may depend greatly on a rapid and accurate diagnosis of the responsible pathogen.

Unfortunately, rapidly delivering accurate results has been a challenge for traditional diagnostic methods. This potentially increases the chance that patients remain undiagnosed or misdiagnosed and may end up not receiving critical medications, or receive unnecessary antibiotics.

Rapid and accurate diagnostic testing for respiratory pathogens may aid healthcare providers in diagnosing patients, which may improve patient management, help limit the spread of disease, and reduce overall healthcare costs.



Setting up the FilmArray is Easy – Sample in, Results out



Clinical Sensitivity and Specificity of the FilmArray Respiratory Pouch

Pathogens	Sensitivity		Specificity
	Prospective	Retrospective	Prospective
Adenovirus	88.9%	100%	98.3%
Coronavirus HKU1	95.8%	n/a	99.8%
Coronavirus NL63	95.8%	n/a	100%
Coronavirus 229E	100%	100%	99.80%
Coronavirus OC43	100%	100%	99.60%
Human Metapneumovirus	94.6%	n/a	99.2%
Human Rhinovirus/Enterovirus	92.7%	95.7%	94.6%
Influenza A	90.0%	n/a	99.8%
Influenza A/H1	n/a	100%	100%
Influenza A/H3	n/a	100%	100%
Influenza A/H1-2009	88.9%*	100%	99.6%
Influenza B	n/a	100%	100%
Parainfluenza Virus 1	100%*	97.1%	99.9%
Parainfluenza Virus 2	87.4%*	100%	99.8%
Parainfluenza Virus 3	95.8%	100%	98.8%
Parainfluenza Virus 4	100%*	100%	99.9%
Respiratory Syncytial Virus	100%	n/a	89.1%
<i>Bordetella pertussis</i>	100%*	94.6%	99.90%
<i>Chlamydomphila pneumoniae</i>	100%*	100% [†]	100%
<i>Mycoplasma pneumoniae</i>	100%*	84.4%	100%

[†]Spiked *Chlamydomphila pneumoniae* samples were used to test retrospective sensitivity.

*Due to low prevalence in the prospective study, clinical sensitivity for these pathogens was based on less than 10 positive samples.

1. Cooper RJ, Hoffman JR, Bartlett JG, et al: Principles of appropriate antibiotic use for acute pharyngitis in adults: Background. Ann Intern Med. 2001, 134: 509-517.

The purchase of FilmArray System includes a limited, non-transferable license under U.S. Patent No. 5,871,908, owned by Evotec Biosystems GmbH and licensed to Roche Diagnostics GmbH, to use only the enclosed amount of product according to the specified protocols. No right is conveyed, expressly, by implication, or by estoppel, to use any instrument or system under any claim of U.S. Patent No. 5,871,908, other than for the amount of product contained herein.

The purchase of this product includes a limited, non-transferable instrument license under specific claims of one or more U.S. patents as listed on BioFire Diagnostics, Inc.'s Web site (<http://www.biofiredx.com/LegalNotices/>) (the "Web Site") and owned by the University of Utah Research Foundation and/or BioFire Diagnostics, Inc. Any kits sold with this product and/or discussed herein (i) may be covered by one or more of the U.S. patents, as listed on the Web Site for the product and (ii) include a limited, nontransferable license to use the enclosed amount(s) in such kits according to the specified protocols.

CE IVD For in vitro diagnostic use. Products are region specific and may not be approved in some countries/regions. Please contact BioFire Diagnostics to obtain the appropriate information for your country of residence.

MRKT-PRT-0229-03